SCHEMBL31653966

SCHEMBL31653966

O=c1oc2cc(O)c(O)cc2c2c1CCC2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.68
KDM4E B2RXH2 9/20 0.68
HSD17B10 Q99714 8/20 0.68
HPGD P15428 6/20 0.68
TSHR P16473 6/20 0.68
MAPT P10636 4/20 0.68
GLA P06280 3/20 0.68
GAA P10253 3/20 0.68
CASP1 P29466 3/20 0.68
CASP7 P55210 3/20 0.68
MAPK1 P28482 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
MAOA P21397 1/20 0.66
CYP1A2 P05177 1/20 0.59
ALDH1A2 O94788 2/20 0.58
ALDH2 P05091 2/20 0.58
ALDH1B1 P30837 2/20 0.58
ALDH1A3 P47895 1/20 0.58
RAB9A P51151 1/20 0.58
MEN1 O00255 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13840361 0.96 ALDH1A1 (0.72) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL14514720 0.90 ALDH1A1 (0.64) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL4708695 0.87 ALDH1A1 (0.63) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL4710620 0.83 ALDH1A1 (0.65) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL30465071 0.83 ALDH1A1 (0.65) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL8805983 0.83 ALDH1A1 (0.65) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL4711029 0.81 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL14262763 0.80 ALDH1A1 (0.97) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL4759826 0.80 ALDH1A1 (0.69) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL20250791 0.80 ALDH1A1 (0.56) ALDH1A1KDM4EHSD17B10HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213569-A1 METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY NEW YORK UNIVERSITY (US) 2025-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213569-A1 METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY DCLRE1B, RNASE1, ADAR ALDH1A1 3389/4885KDM4E 4082/4885HSD17B10 3164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.